Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Amgen · Phase 1 · Completed · Enrollment 349

NCT07313761

ArmPopulationDoseWeeksEstimandWeight change
Maridebart Cafraglutide SC Presentation 1Obesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide SC Presentation 2Obesity or overweightn/rn/rn/rn/r